Literature DB >> 27160907

HCMV vCXCL1 Binds Several Chemokine Receptors and Preferentially Attracts Neutrophils over NK Cells by Interacting with CXCR2.

Rachel Yamin1, Laura S M Lecker2, Yiska Weisblum3, Alon Vitenshtein1, Vu Thuy Khanh Le-Trilling4, Dana G Wolf3, Ofer Mandelboim5.   

Abstract

HCMV is a highly sophisticated virus that has developed various mechanisms for immune evasion and viral dissemination throughout the body (partially mediated by neutrophils). NK cells play an important role in elimination of HCMV-infected cells. Both neutrophils and NK cells utilize similar sets of chemokine receptors to traffic, to and from, various organs. However, the mechanisms by which HCMV attracts neutrophils and not NK cells are largely unknown. Here, we show a unique viral protein, vCXCL1, which targets three chemokine receptors: CXCR1 and CXCR2 expressed on neutrophils and CXCR1 and CX3CR1 expressed on NK cells. Although vCXCL1 attracted both cell types, neutrophils migrated faster and more efficiently than NK cells through the binding of CXCR2. Therefore, we propose that HCMV has developed vCXCL1 to orchestrate its rapid systemic dissemination through preferential attraction of neutrophils and uses alternative mechanisms to counteract the later attraction of NK cells.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27160907     DOI: 10.1016/j.celrep.2016.04.042

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  20 in total

1.  P2Y2 purinergic receptor modulates virus yield, calcium homeostasis, and cell motility in human cytomegalovirus-infected cells.

Authors:  Saisai Chen; Thomas Shenk; Maciej T Nogalski
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-03       Impact factor: 11.205

Review 2.  Chemokines encoded by herpesviruses.

Authors:  Sergio M Pontejo; Philip M Murphy
Journal:  J Leukoc Biol       Date:  2017-08-28       Impact factor: 4.962

Review 3.  Origins of natural killer cell memory: special creation or adaptive evolution.

Authors:  Kayla A Holder; Emilie M Comeau; Michael D Grant
Journal:  Immunology       Date:  2018-02-15       Impact factor: 7.397

4.  The Helicobacter pylori HopQ outermembrane protein inhibits immune cell activities.

Authors:  Chamutal Gur; Naseem Maalouf; Markus Gerhard; Bernhard B Singer; Johanna Emgård; Violeta Temper; Tzahi Neuman; Ofer Mandelboim; Gilad Bachrach
Journal:  Oncoimmunology       Date:  2019-01-29       Impact factor: 8.110

5.  Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1.

Authors:  Chamutal Gur; Naseem Maalouf; Amjad Shhadeh; Orit Berhani; Bernhard B Singer; Gilad Bachrach; Ofer Mandelboim
Journal:  Oncoimmunology       Date:  2019-03-27       Impact factor: 8.110

6.  Evaluation of the Mechanism of Jiedu Huazhuo Quyu Formula in Treating Wilson's Disease-Associated Liver Fibrosis by Network Pharmacology Analysis and Molecular Dynamics Simulation.

Authors:  Shao-Peng Huang; Sen Chen; Yan-Zhen Ma; An Zhou; Hui Jiang; Peng Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-06       Impact factor: 2.650

Review 7.  Chemokine Subversion by Human Herpesviruses.

Authors:  Sergio M Pontejo; Philip M Murphy; James E Pease
Journal:  J Innate Immun       Date:  2018-08-30       Impact factor: 7.349

8.  Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20.

Authors:  Yoav Charpak-Amikam; Tobias Kubsch; Einat Seidel; Esther Oiknine-Djian; Noemi Cavaletto; Rachel Yamin; Dominik Schmiedel; Dana Wolf; Giorgio Gribaudo; Martin Messerle; Luka Cicin-Sain; Ofer Mandelboim
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

9.  TGF-β1 Downregulates the Expression of CX3CR1 by Inducing miR-27a-5p in Primary Human NK Cells.

Authors:  Stefano Regis; Fabio Caliendo; Alessandra Dondero; Beatrice Casu; Filomena Romano; Fabrizio Loiacono; Alessandro Moretta; Cristina Bottino; Roberta Castriconi
Journal:  Front Immunol       Date:  2017-07-25       Impact factor: 7.561

10.  Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL).

Authors:  Shlomo Elias; Shira Kahlon; Rebecca Kotzur; Noah Kaynan; Ofer Mandelboim
Journal:  Oncoimmunology       Date:  2018-02-12       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.